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The prevalence of hypertension (1) and of valvular aortic 
stenosis (2) increase with age, and both hypertension 
(3,4) and valvular aortic stenosis (5) cause left ventricular 
hypertrophy. Both hypertension (1,3) and valvular aortic 
stenosis (2,6) are also associated with an increased incidence 
of cardiovascular events and mortality. Hypertension 
(either a systolic blood pressure of 140 mmHg and higher 
or a diastolic blood pressure of 90 mmHg and higher) was 
present in 132 of 180 persons (73%), mean age 82 years, 
with mild valvular aortic stenosis (7), in 1,238 of 1,720 
persons (72%), mean age 67 years, with asymptomatic mild-
to-moderate valvular aortic stenosis (8), and in 153 of 225 
patients (68%), mean age 68 years, with severe valvular 
aortic stenosis (9). Hypertension is a risk factor for aortic 
stenosis (7,10,11) and is associated with progression of 
aortic stenosis (7). Hypertension is also associated with 
aortic valve calcification (10-13). In a study of 3.39 million 
hospital discharges in Ireland, hypertension was associated 
with aortic stenosis with an odds ratio of 4.0 (14). At 
4.3-year follow-up of 1,656 patients, mean age 67 years, 
with asymptomatic mild-to-moderate valvular aortic 
stenosis, in Cox regression analyses, each 15 g/m higher 
baseline left ventricular mass index predicted increases 
of 12% for major cardiovascular events, of 28% for 
ischemic cardiovascular events, of 34% for cardiovascular 
mortality, and of 23% for combined total mortality 
and hospitalization for heart failure independent of 
confounders (15). A progressive increase in left ventricular 
mass index during follow-up of each 15 g/m increase was 
consistently associated with a 13% to 61% increase in 
cardiovascular events independent of other variables (15). 
The American College of Cardiology/American Heart 
Association valvular heart disease guidelines (16) and the 
European Society of Cardiology/European Association 
for Cardio-Thoracic Surgery valvular heart disease 
guidelines (17) recommend the treatment of hypertension in 
patients with valvular aortic stenosis with antihypertensive 
drug therapy but do not specify which antihypertensive 
drugs should be used. These guidelines recommend 
treatment of hypertension with aortic stenosis of any 
severity with emphasis on careful titration and blood 
pressure monitoring (16,17). In the absence of randomized 
controlled clinical trial data, on the basis of expert medical 
opinion, this author recommends reducing the blood 
pressure in patients with valvular aortic stenosis to less than 
130/80 mmHg with an emphasis on careful titration and 
blood pressure monitoring. 
Systemic hypertension in low-gradient severe valvular 
aortic stenosis with a preserved left ventricular ejection 
fraction causes increased left ventricular filling pressure 
and pulmonary hypertension with development of dyspnea. 
Treatment of hypertension in these patients with vasodilator 
therapy caused a reduction of left ventricular afterload with 
a lowering in left ventricular filling pressure and pulmonary 
artery pressure (18).
 There are limited data on randomized controlled trials 
of treating hypertension in patients with valvular aortic 
stenosis. The Symptomatic Cardiac Obstruction-Pilot Study 
of enalapril in Aortic Stenosis (SCOPE-AS) randomized 56 
patients with symptomatic severe valvular aortic stenosis 
to enalapril or to double-blind placebo (19). Enalapril was 
started at a dose of 2.5 mg twice daily which was increased 
to a dose of 10 mg twice daily. Enalapril was tolerated 
without syncope or hypotension when the left ventricular 
ejection fraction was preserved. The patients who tolerated 
enalapril had a significant improvement in New York Heart 
Association functional class, in the Borg dyspnea index, and 
in the 6-minute walk distance at 4 and 12 weeks (19). 
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A prospective, double-blind, placebo-controlled trial 
randomized 100 patients with asymptomatic moderate 
or severe valvular aortic stenosis to ramipril 10 mg daily 
or to placebo for 1 year (20). The primary endpoint of 
left ventricular mass at 1-year follow-up was significantly 
reduced by enalapril with a reduction of 3.9 g in patients 
treated with ramipril and an increase of 4.5 g in patients 
treated with placebo (20). At 1 year, the aortic valve area 
was not changed in patients treated with ramipril and 
was reduced 0.2 cm2 in patients treated with placebo. 
Systolic blood pressure was reduced by 5.5 mmHg at 
1 year in patients treated with ramipril and by 2.9 mmHg 
in patients treated with placebo. The change in peak tissue 
Doppler systolic velocity at 1 year was 0.03 m/s for patients 
treated with ramipril and 0.12 m/s for patients treated 
with placebo. There was no significant difference in major 
adverse cardiac events between the ramipril group and the 
placebo group (20).
A study was performed in 123 patients who had 2 serial 
electron beam computed tomographic scans for determining 
the rate of change in volumetric aortic valve calcium scores 
during a mean interval of 2.5 years (21). Eighty of the 123 
patients (65%) were treated with angiotensin-converting 
enzyme inhibitors. Progression of aortic valve calcium was 
71% significantly lower in the patients who were treated 
with angiotensin-converting enzyme inhibitors (21). 
Of 2,117 patients, mean age 73 years, with aortic stenosis, 
699 (33%) were treated with angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers (22). At 
4.2-year mean follow-up, patients treated with angiotensin-
converting enzyme inhibitors or angiotensin receptor 
blockers had a significant reduction in all-cause mortality of 
24% and a significant reduction in cardiovascular events of 
23% (22).
There are no clinical trials comparing the use of different 
antihypertensive drugs in the treatment of hypertension in 
patients with valvular aortic stenosis. On the basis of the 
available data, it is reasonable to use angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers in the 
treatment of hypertension in patients with valvular aortic 
stenosis. I would use beta blockers in these patients if 
they have a prior myocardial infarction, angina pectoris, 
a reduced left ventricular ejection fraction, ventricular 
arrhythmias, or supraventricular arrhythmias. Diuretics 
should be used very cautiously if there are small left 
ventricular chamber dimensions. 
There are no clinical trials comparing the use of different 
antihypertensive drugs in the treatment of hypertension 
in patients with aortic regurgitation. Antihypertensive 
drug therapy should be used in these patients with drugs 
used that do not slow the ventricular rate. One study that 
randomized 143 asymptomatic patients with severe aortic 
regurgitation and normal left ventricular systolic function 
to nifedipine 20 mg twice daily or to digoxin 0.25 mg daily 
demonstrated that use of nifedipine reduced or delayed the 
need for aortic valve replacement (23). However, another 
study of 95 patients with asymptomatic severe aortic 
regurgitation and normal left ventricular ejection fraction 
randomized to nifedipine 20 mg every 12 hours, enalapril 
20 mg daily, or to no treatment demonstrated at 7-year 
mean follow-up that long-term treatment with enalapril or 
nifedipine did not reduce or delay the need for aortic valve 
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